News & Updates
Excerpt from the Press Release: BEVERLY, Mass.–(BUSINESS WIRE)–Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today that the first participants have been dosed in a Phase II open-label trial of AKS-452, its protein subunit COVID-19 vaccine candidate. Fifty-two volunteers will receive either one- or two-dose regimens as part of the Phase II…
Read More
Excerpt from the Press Release: Digital healthcare adoption has accelerated since the onset of the pandemic. In the first half of 2021, approximately $14.7B was invested in digital healthcare in the US, surpassing the total amount invested in 2020 (~$14B). Building on a world-class talent pool, AI startups are also booming in Canada with ~$1.4B raised in the first 6…
Read More
Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study “Prediction of immunotherapy response in melanoma through combined modeling of neoantigen burden and immune-related resistance mechanisms,”(1) in Clinical Cancer Research, a journal published by the American Association for…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the first patient has been dosed in a Phase 1, multicenter, open-label, dose-escalation, and dose expansion study to evaluate the safety, pharmacokinetics (PK), and anti-tumor activity…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the first patient has been dosed in a Phase 1, multicenter, open-label, dose-escalation, and dose expansion study to evaluate the safety, pharmacokinetics (PK), and anti-tumor activity…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced today that the Company has received approval for a Clinical Trial Application (CTA) from…
Read More
Excerpt from the Press Release: DUBLIN, Ireland and BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) — Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced a clinical collaboration with Roche to evaluate a novel combination of Carrick’s samuraciclib and Roche’s giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer. The collaboration…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced a significant expansion of its clinical development program for setmelanotide with five new planned Phase 2 and 3…
Read More
Excerpt from the Press Release: TOLEDO, Ohio & PHILADELPHIA–(BUSINESS WIRE)–NAMSA, the world’s only 100% medical device-focused Contract Research Organization (CRO) providing full continuum development solutions, announced today its acquisition of Clinlogix, a leading, Philadelphia-based global clinical research organization. Third in an advancing series, this acquisition follows NAMSA’s purchase announcements of Syntactx and American Preclinical Services (APS) in early…
Read More
Excerpt from the Press Release: PHILADELPHIA, Aug. 2, 2021 /PRNewswire/ — Scientists at Children’s Hospital of Philadelphia (CHOP) have identified two proteins that could be used for a potential vaccine against nontypeable Haemophilus influenzae (NTHi). Working in a mouse model, the investigators found that administering two bacterial adhesive proteins that play a key role in helping the bacteria to latch on…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?